Ethnicity influences phenotype and clinical outcomes: Comparing a South American with a North American inflammatory bowel disease cohort.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
09 Sep 2022
09 Sep 2022
Historique:
entrez:
10
9
2022
pubmed:
11
9
2022
medline:
14
9
2022
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD), has emerged as a global disease with an increasing incidence in developing and newly industrialized regions such as South America. This global rise offers the opportunity to explore the differences and similarities in disease presentation and outcomes across different genetic backgrounds and geographic locations. Our study includes 265 IBD patients. We performed an exploratory analysis of the databases of Chilean and North American IBD patients to compare the clinical phenotypes between the cohorts. We employed an unsupervised machine-learning approach using principal component analysis, uniform manifold approximation, and projection, among others, for each disease. Finally, we predicted the cohort (North American vs Chilean) using a random forest. Several unsupervised machine learning methods have separated the 2 main groups, supporting the differences between North American and Chilean patients with each disease. The variables that explained the loadings of the clinical metadata on the principal components were related to the therapies and disease extension/location at diagnosis. Our random forest models were trained for cohort classification based on clinical characteristics, obtaining high accuracy (0.86 = UC; 0.79 = CD). Similarly, variables related to therapy and disease extension/location had a high Gini index. Similarly, univariate analysis showed a later CD age at diagnosis in Chilean IBD patients (37 vs 24; P = .005). Our study suggests a clinical difference between North American and Chilean IBD patients: later CD age at diagnosis with a predominantly less aggressive phenotype (39% vs 54% B1) and more limited disease, despite fewer biological therapies being used in Chile for both diseases.
Identifiants
pubmed: 36086782
doi: 10.1097/MD.0000000000030216
pii: 00005792-202209090-00110
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30216Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Uhlig HH, Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol. 2018;36:755–81.
Shi HY, Levy AN, Trivedi HD, et al. Ethnicity influences phenotype and outcomes in inflammatory bowel disease: a systematic review and meta-analysis of population-based studies. Clin Gastroenterol Hepatol. 2018;16:190–7.e11.
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66.
Barnes EL, Loftus EV Jr, Kappelman MD. Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases. Gastroenterology. 2021;160:677–89.
Denson LA, Curran M, McGovern DPB, et al. Challenges in IBD research: precision medicine. Inflamm Bowel Dis. 2019;25(suppl 2):S31–9.
Plant D, Barton A. Machine learning in precision medicine: lessons to learn. Nat Rev Rheumatol. 2021;17:5–6.
Seyed Tabib NS, Madgwick M, Sudhakar P, et al. Big data in IBD: big progress for clinical practice. Gut. 2020;69:1520–32.
Goecks J, Jalili V, Heiser LM, et al. How machine learning will transform biomedicine. Cell. 2020;181:92–101.
Alonso-Betanzos A, Bolón-Canedo V. Big-data analysis, cluster analysis, and machine-learning approaches. Adv Exp Med Biol. 2018;1065:607–26.
Damas OM, Jahann DA, Reznik R, et al. Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol. 2013;108:231–9.
Harrison CJ, Sidey-Gibbons CJ. Machine learning in medicine: a practical introduction to natural language processing. BMC Med Res Methodol. 2021;21:158.
Uddin S, Khan A, Hossain ME, et al. Comparing different supervised machine learning algorithms for disease prediction. BMC Med Inform Decis Mak. 2019;19:281.
Fawagreh K, Gaber MM, Elyan E. Random forests: from early developments to recent advancements. Syst Sci Control Eng. 2014;2:602–9.
Goutte C, Gaussier E. A probabilistic interpretation of precision, recall and F-score, with implication for evaluation. Lect Notes Comput Sci. 2005;3408:345–59.
Wu Q, Wang W. Piecewise-smooth support vector machine for classification. Math Probl Eng. 2013;2013:135149.
Hatwell J, Gaber MM, Atif Azad RM. Ada-WHIPS: explaining adaboost classification with applications in the health sciences. BMC Med Inform Decis Mak. 2020;20:250.
Abirami S, Chitra P. Chapter fourteen – energy-efficient edge based real-time healthcare support system. Raj P, Evangeline P, eds. In: The Digital Twin Paradigm for Smarter Systems and Environments: The Industry Use Cases. Vol 117. Advances in Computers. Amsterdam, Netherlands: Elsevier, 2020:339–68.
Currie G, Hawk KE, Rohren E, et al. Machine learning and deep learning in medical imaging: intelligent imaging. J Med Imaging Radiat Sci. 2019;50:477–87.
Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145:996–1006.
Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–8.
Monstad IL, Solberg IC, Cvancarova M, et al. Outcome of ulcerative colitis 20 years after diagnosis in a prospective population-based inception cohort from south-eastern Norway, the IBSEN study. J Crohn’s Colitis. 2021;15:969–79.
Ministerio de Salud. Gobierno de Chile. Tratamiento con infliximab o adalimumab para personas con enfermedad de crohn grave refractaria a tratamiento habitual. Available at: https://www.minsal.cl/wp-content/uploads/2019/07/6.-10072019-Protocolo-CROHN-II_FINAL.pdf . [access date January 24, 2022].
Minsal. Tratamiento con golimumab o adalimumab para personas con colitis ulcerosa moderada e infliximab en personas con colitis ulcerosa grave, refractaria al tratamiento de primera línea. 2019. Available at: https://www.minsal.cl/wp-content/uploads/2019/07/20.-10072019-Protocolo-CUlcerosa_FINAL.pdf . [access date January 24, 2022].
Greywoode R, Petralia F, Ullman T, et al. DOP58 Non-white race is associated with decreased efficacy of tumor necrosis factor antagonist therapy in ulcerative colitis: a posthoc analysis of individual level data from golimumab clinical trials. J Crohn’s Colitis. 2021;15(suppl_1):S093–4.
Ungar B, Haj-Natour O, Kopylov U, et al. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. Medicine (Baltim). 2015;94:e673.
Kim ES, Park DI, Kim HJ, et al. DOP67 Comparison of the pharmacokinetics of CT-P13 between Crohn’s disease and ulcerative colitis in biologic-naïve patients; a prospective multi-center observational study of the KASID. J Crohn’s Colitis. 2021;15(suppl_1):S101–2.
Ruel J, Ruane D, Mehandru S, et al. IBD across the age spectrum – is it the same disease? Nat Rev Gastroenterol Hepatol. 2014;11:88–98.
Jolliffe IT, Cadima J. Principal component analysis: a review and recent developments. Philos Trans A Math Phys Eng Sci. 2016;374:20150202.
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–17.
Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.
Cross RK, Jung C, Wasan S, et al. Racial differences in disease phenotypes in patients with Crohn’s disease. Inflamm Bowel Dis. 2006;12:192–8.
Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012–23.
Hou J, El-Serag H, Sellin J, et al. Inflammatory bowel disease characteristics and treatment in Hispanics and Caucasians. Dig Dis Sci. 2011;56:1476–81.
Hernández Cruz B, Alonso F, Calvo Alén J, et al. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus. 2020;29:27–36.
Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156–67.
Cleynen I, González JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European project. Gut. 2013;62:1556–65.
Dulai PS, Singh S, Vande Casteele N, et al. Should we divide Crohn’s disease into ileum-dominant and isolated colonic diseases? Clin Gastroenterol Hepatol. 2019;17:2634–43.
Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003;52:552–7.
Guizzetti L, Zou G, Khanna R, et al. Development of clinical prediction models for surgery and complications in Crohn’s disease. J Crohn’s Colitis. 2018;12:167–77.
Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2021;18:544–58.
Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9:670–8.e3.
Reinisch W, Colombel JF, D’Haens G, et al. Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn’s disease: results from the EXTEND trial. J Crohn’s Colitis. 2017;11:425–34.
Danese S, Sandborn WJ, Colombel JF, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn’s disease. Gastroenterology. 2019;157:1007–18.e7.
Tyler CJ, Guzman M, Lundborg LR, et al. Inherent immune cell variation within colonic segments presents challenges for clinical trial design. J Crohn’s Colitis. 2020;14:1364–77.
Smids C, Horjus Talabur Horje CS, van Wijk F, et al. The complexity of alpha E beta 7 blockade in inflammatory bowel diseases. J Crohn’s Colitis. 2017;11:500–8.
Lueschow SR, McElroy SJ. The paneth cell: the curator and defender of the immature small intestine. Front Immunol. 2020;11:587.
Jung C, Hugot J-P, Barreau F. Peyer’s patches: the immune sensors of the intestine. Int J Inflam. 2010;2010:1–12.
Ha CWY, Martin A, Sepich-Poore GD, et al. Translocation of viable gut microbiota to mesenteric adipose drives formation of creeping fat in humans. Cell. 2020;183:666–683.e17.
Kredel LI, Jödicke LJ, Scheffold A, et al. T-cell composition in ileal and colonic creeping fat – separating ileal from colonic Crohn’s disease. J Crohn’s Colitis. 2019;13:79–91.
van der Meer JHM, Wasmann KATGM, van der Bilt JDW, et al. Anatomical variation in mesenteric macrophage phenotypes in Crohn’s disease. Clin Transl Gastroenterol. 2020;11:e00198.
Palmela C, Chevarin C, Xu Z, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 2018;67:574–87.
Chervy M, Barnich N, Denizot J. Adherent-invasive E. coli : update on the lifestyle of a troublemaker in Crohn’s disease. Int J Mol Sci. 2020;21:1–34.
Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–92.
Lopez-Siles M, Martinez-Medina M, Busquets D, et al. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes. Int J Med Microbiol. 2014;304:464–75.
Clooney AG, Eckenberger J, Laserna-Mendieta E, et al. Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut. 2021;70:499–510.
Chen X, Ishwaran H. Random forests for genomic data analysis. Genomics. 2012;99:323–9.
Han S, Williamson BD, Fong Y. Improving random forest predictions in small datasets from two-phase sampling designs. BMC Med Inform Decis Mak. 2021;21:322.
Robinson GA, Peng J, Dönnes P, et al. Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatol. 2020;2:e485–96.